Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

ReNeuron provides update for hRPC therapy candidate study

June 10, 2021

New PDE6C and PDE5A inhibitors discovered at ILDONG Pharmaceutical

June 9, 2021

Preliminary phase I data for ST-266 in glaucoma suspect patients

June 8, 2021

Optogenetic vector GS030-DP with light stimulation shows promise in retinitis pigmentosa patient

June 7, 2021

Multi-characteristic opsin gene therapy restores clinically meaningful vision in patients with RP

June 4, 2021

Oyster Point expands its pipeline and announces promising preclinical data

June 4, 2021

Targeting tenascin-C could reduce the effects of retinal ischemia

June 2, 2021

Preclinical results presented for a gene therapy to treat CDHR1-related retinopathy

May 27, 2021

New PARP-1 inhibitors described by Kukje Pharma, Chungnam National University

May 26, 2021

NCX-667 demonstrates IOP-lowering ability in a number of animal models

May 26, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...